Combination therapy with volasertib
AssigneeBoehringer Ingelheim International GmbH
InventorTillmann TAUBE
Life of this patent
Estimating the term…
Abstract
Disclosed is the use of Volasertib or a salt or a hydrate thereof for treating patients suffering from acute myeloid leukemia (AML) comprising administering a high dose of Volasertib in combination with fludarabine, cytarabine and Granulocyte colony-stimulating factor (GCSF) or in combination with fludarabine, cytarabine, GCSF and a daunorubicin citrate liposome injection.
Claims5
A method of treating acute myeloid leukemia (AML) comprising administration to a patient suffering from AML
- a) an effective amount (50-500 μg/m2 body surface area) of GCSF at day 0, 1, 2, 3, 4 and 5 during a 6 day treatment cycle (days 0 to 5);
- b) an effective amount (10-100 mg/m2 body surface area) of fludarabine at day 1, 2, 3, 4 and 5 during said 6 day treatment cycle;
- c) an effective amount (500-4000 mg/m2 body surface area) of cytarabine at day 1, 2, 3, 4 and 5 during said 6 day treatment cycle;
- and
- d) an effective amount (10 to 350 mg/m2 body surface area) of Volasertib, or a pharmaceutically acceptable salt or hydrate thereof, at least one day up to 5 days during said 6 day treatment cycle.
A method of treating acute myeloid leukemia (AML) comprising administration to a patient suffering from AML
- a) an effective amount (50-500 μg/m2 body surface area) of GCSF by i.v. infusion at day 0, 1, 2, 3, 4 and 5 during a 6 day treatment cycle (days 0 to 5),
- b) an effective amount (10-100 mg/m2 body surface area) of fludarabine at day 1, 2, 3, 4 and 5 during said 6 day treatment cycle,
- c) an effective amount (500-4000 mg/m2 body surface area) of cytarabine at day 1, 2, 3, 4 and 5 during said 6 day treatment cycle,
- d) an effective amount (500-4000 mg/m2 body surface area) of daunorubicin citrate liposome at day 1, 3 and 5 during said 6 day treatment cycle, and
- e) an effective amount (10 to 350 mg/m2 body surface area) of Volasertib, or a pharmaceutically acceptable salt or hydrate thereof, at least one day up to 5 days during said 6 day treatment cycle.
A pharmaceutical composition comprising an effective amount of fludarabine, cytarabine and GCSF optionally together with an instruction for administration of the active ingredients to a patient suffering from AML, wherein the composition additionally comprises an effective amount of Volasertib or a pharmaceutically acceptable salt or hydrate thereof.
Dependencies are inferred from the claim text.